Close Menu

NEW YORK (GenomeWeb) – Qiagen said after the close of the market on Wednesday that Laboratory Corporation of America has joined its "Day-One" lab readiness program designed to expedite patient access to Qiagen companion diagnostic products following regulatory approval of the tests and associated drugs.

Qiagen's Day-One program is intended to enable molecular diagnostic labs to begin preparing for commercial launch of new drugs and in vitro diagnostic tests being developed by Qiagen and its partners once US Food and Drug Administration approval is obtained.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.